KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $201.6 million.

  • Halozyme Therapeutics' Cash from Investing Activities rose 220.38% to $201.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.5 million, marking a year-over-year increase of 175.03%. This contributed to the annual value of -$262.7 million for FY2024, which is 171.10% down from last year.
  • Halozyme Therapeutics' Cash from Investing Activities amounted to $201.6 million in Q3 2025, which was up 137.78% from $84.8 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash from Investing Activities registered a high of $201.6 million during Q3 2025, and its lowest value of -$434.9 million during Q2 2022.
  • In the last 3 years, Halozyme Therapeutics' Cash from Investing Activities had a median value of -$42.0 million in 2024 and averaged -$14.9 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Cash from Investing Activities crashed by 8,178.77% in 2023 and then spiked by 455.57% in 2024.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Cash from Investing Activities stood at -$299.5 million in 2021, then skyrocketed by 99.42% to -$1.7 million in 2022, then slumped by 374.86% to -$8.3 million in 2023, then skyrocketed by 455.57% to $29.5 million in 2024, then spiked by 220.38% to $201.6 million in 2025.
  • Its Cash from Investing Activities stands at $201.6 million for Q3 2025, versus $84.8 million for Q2 2025 and -$90.4 million for Q1 2025.